Medical Oncology

, Volume 29, Issue 2, pp 761–767 | Cite as

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

  • Naomi B. Haas
  • Xinyi Lin
  • Judith Manola
  • Michael Pins
  • Glenn Liu
  • David McDermott
  • David Nanus
  • Elisabeth Heath
  • George Wilding
  • Janice Dutcher
Original Paper


Sarcomatoid features can arise in renal cell carcinoma of any subtype and are associated with a poor prognosis. Doxorubicin and gemcitabine in a limited series showed activity in aggressive renal tumors and we wished to formally assess the combination in patients with renal cell carcinoma specifically containing sarcomatoid features. The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of doxorubicin 50 mg/m2 IV push and gemcitabine 1,500 mg/m2 IV over 30 min every 2 weeks in 39 patients with locally advanced or metastatic renal cell carcinoma with sarcomatoid features. Ten patients (26%) had grade 3 toxicity, and four patients (11%) had grade 4 toxicities. Although most toxicity was from myelosuppression, one patient died on study from cardiac dysfunction after a cumulative dose of 450 mg/m2 doxorubicin. Six (16%) patients experienced responses (5 partial responses and 1 complete response), and ten (26%) patients had stable disease. In addition, another patient had an unconfirmed partial response and an additional patient experienced over 50% decrease in her tumor burden after an initial progression. The median overall survival was 8.8 months, and the median progression-free survival was 3.5 months. We conclude that the combination of doxorubicin and gemcitabine, inactive in patients with mostly clear cell histology, demonstrated responses in patients with RCC with sarcomatoid features. We acknowledge the toxicity of this combination but note that limited treatment options exist for this aggressive histology. Only through prospective multicenter trials with comprehensive central pathology review will better treatment options be identified.


Sarcomatoid Gemcitabine Doxorubicin Renal cell cancer Kidney cancer 


  1. 1.
    Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer. 2001;91(2):354–61.Google Scholar
  2. 2.
    Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5.Google Scholar
  3. 3.
    Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Ficarra V, Prayer-Galetti T, Novella G, et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol. 2003;43:663–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Patard JJ, Leray E, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid Renal Cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435–41.PubMedCrossRefGoogle Scholar
  8. 8.
    de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:64–275.Google Scholar
  9. 9.
    Jones TD, Eble JN, Wang M, et al. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer. 2005;104:1195–203.PubMedCrossRefGoogle Scholar
  10. 10.
    Tickoo SK, Alden D, Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1 alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177:1258–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Bangalore N, Bhargava P, Hawkins MJ, et al. Sustained response of sarcomatoid renal cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol. 2001;12:271–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Hoshi S, Satoh M, Ohyama C, Hiramatu M, et al. Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Oncol. 2003;8(2):113–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcinoma: a treatable entity. Cancer. 1987;60:1313–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol. 2002;168(3):959–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004;101(7):1545–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Dutcher JP, Nanus D. Long term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2010;Aug 18 (epub ahead of print).Google Scholar
  17. 17.
    Eble JN. Renal cell carcinoma, unclassified, pg 43. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization Classification of Tumours, Pathology and Genetics. Tumors of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.Google Scholar
  18. 18.
    Langner C, von Wasielewski R, Ratschek M, et al. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch. 2004;445(6):631–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Ishizaki H, Yano H, Tsuneoka M, et al. Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathol Int. 2007;57(10):672–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Visapää H, Seligson D, Huang Y, et al. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol Res. 2003;30(6):387–9.PubMedGoogle Scholar
  21. 21.
    Mertz KD, Demichelis F, Kim R, et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol. 2007;38(10):1454–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Tamboli P, Prieto VG, Bekele BN, et al. The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Proc Am Soc Clin Oncol 2003;22:408a (abstr 1641).Google Scholar
  23. 23.
    Ku JH, Park YH, Myung JK, Moon KC, Kwak C, Kim HH. Expression of hypoxia inducible factor-1alpha and 2alpha in conventional renal cell carcinoma with or without sarcomatoid differentiation. Urol Oncol. 2009;Nov 12.Google Scholar
  24. 24.
    Golshayan AR, George S, Heng DY, Elson P, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Vogelzang NJ, Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol. 2010;Oct 25.Google Scholar
  26. 26.
    Haas NB. Paired specimens: an opportunity to answer some important questions. Cancer. 2010;116(3):574–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12(1):144–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Michaelson M, Schwarzberg A, Ryan D, et al. A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. 2008 ASCO Genitourinary Cancers Symposium 362.Google Scholar
  29. 29.
    Pandya SS, Mier JW, Cho D, McDermott D. The Role of adding gemcitabine at time of sunitinib resistance in patients with metastatic RCC. 2008 ASCO Genitourinary Cancers Symposium 380.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Naomi B. Haas
    • 1
  • Xinyi Lin
    • 2
  • Judith Manola
    • 3
  • Michael Pins
    • 4
  • Glenn Liu
    • 5
  • David McDermott
    • 6
  • David Nanus
    • 7
  • Elisabeth Heath
    • 8
  • George Wilding
    • 5
  • Janice Dutcher
    • 9
  1. 1.Abramson Cancer CenterPhiladelphiaUSA
  2. 2.Department of BiostatisticsHarvard School of Public HealthBostonUSA
  3. 3.Dana-Farber Cancer InstituteBostonUSA
  4. 4.Advocate Lutheran General HospitalUniversity of Illinois Chicago College of MedicinePark RidgeUSA
  5. 5.University of Wisconsin Carbone Cancer CenterMadisonUSA
  6. 6.Beth Israel Deaconess Medical CenterBostonUSA
  7. 7.New York Presbyterian HospitalNew YorkUSA
  8. 8.Karmanos Cancer Center InstituteDetroitUSA
  9. 9.Division of Hematology/Oncology, St. Luke’s Roosevelt Hospital Center, Continuum Cancer CentersNew YorkUSA

Personalised recommendations